Loading...
XNAS
PODD
Market cap21bUSD
Jun 10, Last price  
298.73USD
1D
-2.27%
1Q
20.27%
Jan 2017
692.81%
IPO
1,833.53%
Name

Insulet Corp

Chart & Performance

D1W1MN
P/E
50.26
P/S
10.15
EPS
5.94
Div Yield, %
Shrs. gr., 5y
3.47%
Rev. gr., 5y
22.92%
Revenues
2.07b
+22.07%
50,0003,663,00013,372,00036,059,00066,032,00096,966,000152,255,000211,369,000247,084,000288,720,000263,893,000366,989,000463,768,000563,823,000738,200,000904,400,0001,098,800,0001,305,300,0001,697,100,0002,071,600,000
Net income
418m
+102.76%
-21,636,000-35,950,000-53,539,000-92,791,000-79,541,000-61,159,000-57,170,000-51,867,000-44,974,000-51,500,000-73,520,000-28,879,000-26,831,0003,292,00011,600,0006,800,00016,800,0004,600,000206,300,000418,300,000
CFO
430m
+195.33%
-20,321,000-31,820,000-50,372,000-82,611,000-49,323,000-35,625,000-25,452,000-29,059,0003,348,0008,920,000-12,552,00015,911,00041,207,00035,899,00098,400,00084,000,000-68,100,000119,000,000145,700,000430,300,000
Earnings
Aug 06, 2025

Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
IPO date
May 15, 2007
Employees
2,600
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,071,600
22.07%
1,697,100
30.02%
1,305,300
18.79%
Cost of revenue
845,500
742,200
679,900
Unusual Expense (Income)
NOPBT
1,226,100
954,900
625,400
NOPBT Margin
59.19%
56.27%
47.91%
Operating Taxes
(118,100)
8,300
5,200
Tax Rate
0.87%
0.83%
NOPAT
1,344,200
946,600
620,200
Net income
418,300
102.76%
206,300
4,384.78%
4,600
-72.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,900
10,600
(500)
BB yield
-0.06%
-0.07%
0.00%
Debt
Debt current
83,800
49,400
27,500
Long-term debt
1,395,900
1,401,700
Deferred revenue
1,600
Other long-term liabilities
1,347,700
37,900
35,700
Net debt
(869,600)
714,500
739,500
Cash flow
Cash from operating activities
430,300
145,700
119,000
CAPEX
(124,900)
(75,600)
(157,300)
Cash from investing activities
(146,200)
(119,400)
(191,100)
Cash from financing activities
(28,100)
(13,600)
(40,300)
FCF
1,297,500
678,900
589,200
Balance
Cash
953,400
704,200
674,700
Long term investments
26,600
15,000
Excess cash
849,820
645,945
624,435
Stockholders' equity
27,200
(369,900)
(564,200)
Invested Capital
2,615,900
2,556,300
2,479,700
ROIC
51.98%
37.59%
24.92%
ROCE
46.39%
43.67%
32.68%
EV
Common stock shares outstanding
73,890
73,633
69,910
Price
261.07
20.32%
216.98
-26.30%
294.39
10.64%
Market cap
19,290,462
20.74%
15,976,888
-22.37%
20,580,805
12.79%
EV
18,420,862
16,691,388
21,320,305
EBITDA
1,306,900
1,027,700
688,600
EV/EBITDA
14.10
16.24
30.96
Interest
42,700
36,200
26,700
Interest/NOPBT
3.48%
3.79%
4.27%